These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 9916786)

  • 1. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
    Watts NB; Becker P
    Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
    Struys A; Snelder AA; Mulder H
    Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to alendronate in osteoporosis after previous treatment with etidronate.
    Fairney A; Kyd P; Thomas E; Wilson J
    Osteoporos Int; 2000; 11(7):621-5. PubMed ID: 11069197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2005 Dec; 46(6):750-8. PubMed ID: 16385649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
    J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
    Wimalawansa SJ
    Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Ichimura S; Uzawa M
    Keio J Med; 2003 Jun; 52(2):113-9. PubMed ID: 12862363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.
    Yan Y; Wang W; Zhu H; Li M; Liu J; Luo B; Xie H; Zhang G; Li F
    J Bone Miner Metab; 2009; 27(4):471-8. PubMed ID: 19343272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women.
    Masud T; Mulcahy B; Thompson AV; Donnelly S; Keen RW; Doyle DV; Spector TD
    Ann Rheum Dis; 1998 Jun; 57(6):346-9. PubMed ID: 9771208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.
    Sahota O; Fowler I; Blackwell PJ; Lawson N; Cawte SA; San P; Masud T; Hosking DJ
    Osteoporos Int; 2000; 11(11):959-66. PubMed ID: 11193249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of early postmenopausal bone loss with cyclical etidronate.
    Adami S; Bruni V; Bianchini D; Becorpi A; Lombardi P; Campagnoli C; Ferrari A; Marchesoni T; Balena R
    J Endocrinol Invest; 2000 May; 23(5):310-6. PubMed ID: 10882149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.
    Miller PD; Watts NB; Licata AA; Harris ST; Genant HK; Wasnich RD; Ross PD; Jackson RD; Hoseyni MS; Schoenfeld SL; Valent DJ; Chesnut CH
    Am J Med; 1997 Dec; 103(6):468-76. PubMed ID: 9428829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study.
    Herd RJ; Balena R; Blake GM; Ryan PJ; Fogelman I
    Am J Med; 1997 Aug; 103(2):92-9. PubMed ID: 9274891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
    Fogelman I; Herd RJ; Blake GM; Balena R
    Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
    Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
    Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist.
    Zamberlan N; Castello R; Gatti D; Rossini M; Braga V; Fracassi E; Adami S
    Osteoporos Int; 1997; 7(2):133-7. PubMed ID: 9166393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.
    Cortet B; Béra-Louville A; Gauthier P; Gauthier A; Marchandise X; Delcambre B
    Joint Bone Spine; 2001 Oct; 68(5):410-5. PubMed ID: 11707007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study.
    Wimalawansa SJ
    Am J Med; 1995 Jul; 99(1):36-42. PubMed ID: 7598140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.